Disclosures
None.
REFEREN CES
1. Atlas A. Steven. The Renin-Angiotensin Aldosterone System:
Pathophysiological Role and Pharmacologic Inhibition. J Manag care
Pharm. 2010;13:9–20.
2. White PC. Aldosterone: Direct effects on and production by the heart.
J Clin Endocrinol Metab. 2003;88:2376–83.
3. Kaplan NM. Diuretics as a basis of antihypertensive therapy: An
overview. Drugs. 2000;59:21–5.
4. Brater DC. Pharmacology of Diuretics. Am J Med Sci. 2000;319:38–50.
5. Greenberg S, McGowan C, Xie J, Summer WR. Selective pulmonary and
venous smooth muscle relaxation by furosemide: A comparison with
morphine. J Pharmacol Exp Ther. 1994;270:1077–85.
6. Wiemer G, Fink E, Linz W, Hropot M, Scholkens BA, Wohlfart P.
Furosemide enhances the release of endothelial kinins, nitric oxide and
prostacyclin. J Pharmacol Exp Ther. 1994;271:1611–5.
7. Pickkers P, Hughes AD, Russel FGM, Thien T, Smits P. Thiazide-Induced
Vasodilation in Humans Is Mediated by Potassium Channel Activation.
1998;
8. P. LIJNEN, R. FAGARD JS& AA. EFFECT OF CHRONIC DIURETIC TREATMENT ON
THE PLASMA RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN ESSENTIAL
HYPERTENSION. Br J Clin Pharmacol. 1981;12:387–92.
9. Maxwell MH GC. Tricrynafen and hydrochlorothiazide in essential
hypertension. Effect of the renin-angiotensinaldosterone system and on
electrolyte balance. In: A new class of diuretics with uricosuric
activity. Postgrad Med Commun. 1978;5:43–50.
10. Himathongkam T, Dluhy RG WG. Potassim-aldosterone-renin
interrelationships. J Clin Endocrinol Metab. 1975;41:153–9.
11. Williams GH, Tuck ML, Rose LI, Dluhy RG, Underwood RH. Studies of
the control of plasma aldosterone concentration in normal man. 3.
Response to sodium chloride infusion. J Clin Invest. 1972;51:2645–52.
12. EL B. Regulation of aldosterone secretion: current concepts and
newer aspects. adv nephrol. 1977;7:105–20.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement. J
Clin Epidemiol. 2009;62:1006–12.
14. Borenstein, M., Hedges, L., Higgins, J., & Rothstein H.
Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ; 2013.
15. Sutton AJ, Abrams KR, Jones DR, Sheldon TA SF. Methods for
meta-analysis in medical research. 2000.
16. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV,
editor. Cochrane Handbook for Systematic Reviews of Interventions
version 6.0 (updated July 2019). Cochrane; 2019.
17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. Br Med J. 1997;315:629–34.
18. Moser M, Feig PU. Fifty years of thiazide diuretic therapy for
hypertension. Arch Intern Med. 2009;169:1851–6.
19. Roush GC, Sica DA. Diuretics for hypertension: A review and update.
Am J Hypertens. 2016;29:1130–7.
20. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure
lowering on outcome incidence in hypertension.1. Overview,
meta-analyses, and meta-regression analyses of randomized trials. J
Hypertens. 2014;32:2285–95.
21. Wright JT Jr1, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE,
Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL,
Whelton PK HGACRG. Outcomes in hypertensive black and nonblack patients
treated with chlorthalidone, amlodipine, and lisinopril. JAMA - J Am Med
Assoc. 2005;293:1595–608.
22. McNally RJ, Faconti L, Cecelja M, Farukh B, Floyd CN, Chowienczyk
PJ. Effect of diuretics on plasma renin activity in primary
hypertension: A systematic review and meta‐analysis. Br J Clin
Pharmacol. 2021;2189–98.
23. Carey RM. AT2 receptors: Potential therapeutic targets for
hypertension. Am J Hypertens. 2017;30:339–47.
24. Perrone MH, Deborah A, Perrone MH, Physiol C. renin-angiotensin;
an-. 2020;
25. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The
angiotensin AT2-receptor mediates inhibition of cell proliferation in
coronary endothelial cells. J Clin Invest. 1995;95:651–7.
26. Furberg CD. Renin-guided treatment of hypertension: Time for action.
Am J Hypertens [Internet]. Nature Publishing Group; 2010;23:929–30.
Available from: http://dx.doi.org/10.1038/ajh.2010.135
27. McNally RJ, Morselli F, Farukh B, Chowienczyk PJ, Faconti L. A
review of the prescribing trend of thiazide-type and thiazide-like
diuretics in hypertension: A UK perspective. Br J Clin Pharmacol.
2019;85:2707–13.
28. Weber KT, Sun Y, Guarda E. Structural Remodeling in Hypertensive
Heart Disease and the Role of Hormones. 2011;
29. Young M, Dilley R, Funder J. Mineralocorticoids, hypertension, and
cardiac fibrosis. J Clin Invest. 1965;44:1072–116.
30. Atsuhisa Sato JF. High glucose stimulates aldosteronesterone-induced
hypertrophy via type I mineralocorticoid receptors in neonatal rat
cardiomyocytes.
31. Faconti L, McNally RJ, Farukh B, Adeyemi O, Cruickshank JK,
Wilkinson IB, et al. Differences in hypertension phenotypes between
Africans and Europeans: Role of environment. J Hypertens.
2020;38:1278–85.
32. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement
of angiotensin metabolites and in vitro generated angiotensin II in
plasma. Hypertension. 1986;8:476–82.
33. Anton H. van den Meiracker, Peter J.J. Admiraal, Joop A. Janssen,
Jan-Maarten Kroodsma, Wijnand A.M. de Ronde, Frans Boomsma, Joëlle
Sissmann, P.J. Blankestijn, Paul G.M. Mulder, Arie J. Man in ‘t Veld and
MADHS. Hemodynamic and Biochemical Effects of the AT1 Receptor
Antagonist Irbesartan in Hypertension. Hypertension. 1995;25:22–9.
34. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone
abolishes the relationship between aldosterone and plasminogen activator
inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448–52.
35. S Ichikawa, Y Tajima, T Sakamaki, H Matsuo, M Kogure, Y Hirano, S
Yagi KM. Effect of spironolactone on fluid volumes and adrenal steroids
in primary aldosteronism. Circulation. 1984;48:1184–96.